Related Experiment Video
Updated: May 25, 2026
Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
Published on: September 25, 2018
Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL
Jordi Martinez-Serra1, Antonio Gutiérrez, Toni F Marcús
1Department of Hematology, University Hospital of Son Espases, Carretera Valldemossa no. 79, Palma de Mallorca, Spain. jorgej.martinez@ssib.es
Objectives:
Within the laboratory protocols, used for the study of BCR-ABL resistance mutations in chronic myeloid leukemia patients treated with Imatinib, direct sequencing remains the reference method. Since the incidence of patients with a mutation-related loss of response is not very high, it is very useful in the routine laboratory to perform a fast pre-screening method.
Design And Methods:
With this in mind, we have designed a new technique, based on a single Real-Time FRET-based PCR, followed by a study of melting peaks. This new tool, developed in a LightCycler 2.0, combines four different fluorescence channels for the simultaneous detection, in a single close tube, of critical mutations within the ABL kinase domain.
Results:
Assay evaluation performed on 33 samples, previously genotyped by sequentiation, resulted in full concordance of results.
Conclusions:
This new methodology detects in a few steps the presence of critical mutations associated to Imatinib resistance.
Insights
A new Real-Time FRET-based PCR method quickly screens for BCR-ABL resistance mutations in chronic myeloid leukemia (CML) patients treated with Imatinib, improving routine laboratory diagnostics.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacogenomics
Background:
- Direct sequencing is the reference method for detecting BCR-ABL resistance mutations in Imatinib-treated chronic myeloid leukemia (CML) patients.
- A rapid pre-screening method is valuable for routine laboratories due to the low incidence of mutation-related loss of response.
Purpose of the Study:
- To develop and evaluate a novel, rapid pre-screening technique for BCR-ABL resistance mutations.
- To enhance diagnostic efficiency in Imatinib-treated CML patients.
Main Methods:
- A single Real-Time FRET-based PCR assay was designed and developed on a LightCycler 2.0 platform.
- The method utilizes four fluorescence channels for simultaneous detection of critical ABL kinase domain mutations in a closed-tube system.
- Melting peak analysis was employed for mutation detection.
Main Results:
- The newly developed assay demonstrated full concordance with previous sequencing-based genotyping in 33 tested samples.
- The technique allows for the detection of critical mutations associated with Imatinib resistance.
Conclusions:
- This novel Real-Time FRET-based PCR methodology offers a fast and accurate pre-screening tool for BCR-ABL resistance mutations.
- The method streamlines the detection of mutations critical for Imatinib resistance in CML patients.
